Dr. Harpreet Bhatia’s talk on cardiovascular disease and lipid management in patients with MASLD and significant fibrosis. A valuable discussion on an important aspect of MASLD care. @DrLoomba#MASHDAY2026#MASH#MASLD#MASHEDUCATIONDAY
Please to share our article co-authored by @DrLoomba, ALG-055009 shows promise in reducing liver fat and improving lipid profiles in non-cirrhotic MASH patients with a favorable safety profile!
https://t.co/vBuje286Na
@UCSD_GI@LancetGastroHep
New research - ALG-055009 in non-cirrhotic adults with metabolic dysfunction-associated steatohepatitis (HERALD): a randomised, double-blind, placebo-controlled, phase 2a trial
https://t.co/pvYSpbvVkY @DrLoomba#MASH#MASLD#LiverTwitter#MedTwitter
Excited to share the publication of our latest work in @LancetGastroHep evaluating zalfermin and semaglutide in patients with metabolic dysfunction-associated steatohepatitis (MASH) and advanced fibrosis.
🎉@DrLoomba and the entire study team!
Proud that @UCSD_GI is ranked #1 globally in Research & Education in the latest U.S. News rankings powered by Clarivate. Testament to our incredible faculty, trainees, staff & collaborators driving innovation and impact every day.
https://t.co/DyOOuITVUK
From AI-powered outreach to advancing maternal health equity, our Improvement Excellence Awards spotlight teams reimagining care—reducing no-shows, improving access, lowering postpartum readmissions and redirecting medical supplies to communities in need. https://t.co/C3Urf1mCme